🧠 SUBSTANCE P / NEUROKININ-1 RECEPTOR ANTAGONISTS

0.0(0)
Studied by 0 people
call kaiCall Kai
Locked
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/33

encourage image

There's no tags or description

Looks like no tags are added yet.

Last updated 9:34 PM on 6/19/25
Name
Mastery
Learn
Test
Matching
Spaced
Call with Kai
Chat

No analytics yet

Send a link to your students to track their progress

34 Terms

1
New cards

What is Substance P?

A neurokinin peptide neurotransmitter.

2
New cards

What is the primary role of Substance P in chemotherapy?

It is believed to be the primary mediator of delayed chemotherapy-induced nausea and vomiting.

3
New cards

With which medications is Substance P often used?

It is often used with 5-HT3 blockers and corticosteroids.

4
New cards

What is the prototype drug for NK1 receptor antagonists?

Aprepitant (Emend, Cinvanti) - PO and Fosaprepitant (Emend IV) - IV (a prodrug converted to aprepitant).

5
New cards

What is the mechanism of action of Aprepitant?

It blocks NK1 receptors in the brainstem to interrupt the nausea signal.

6
New cards

Does Aprepitant have any effect on serotonin or dopamine receptors?

No, it has no effect on serotonin or dopamine receptors.

7
New cards

What are the indications for using Aprepitant?

Improves control of nausea/vomiting on days 3-5, which 5-HT3 blockers don’t fully cover.

8
New cards

What safety warning is associated with Fosaprepitant?

It should no longer be used in adults/peds for chemo-induced N/V due to risk of abnormal heart rhythm.

9
New cards

What should be monitored when using Fosaprepitant?

Monitor QT interval, especially if used with other risk drugs.

10
New cards

What is the effect of Aprepitant on hormonal contraceptives?

It reduces effectiveness for up to 28 days; a backup method should be used.

11
New cards

What is Aprepitant’s administration method for PO?

Take with or without food, 1 hour before chemo on day 1, then QAM on days 2 & 3.

12
New cards

Why is IV administration of Fosaprepitant discouraged?

Due to QT issues.

13
New cards

What combination of drugs is typically used in the antiemetic regimen including Aprepitant?

Aprepitant + 5-HT3 antagonist + corticosteroid ± olanzapine.

14
New cards

What should be assessed after chemotherapy when using Aprepitant?

Whether nausea/vomiting is controlled.

15
New cards

What are common side effects of Aprepitant?

Fatigue, dizziness, and hiccups.

16
New cards

What contraindications exist for using Aprepitant?

Hypersensitivity to the drug, and use with Ranolazine, Pimozide, and Cisapride due to serious QT and arrhythmia risks.

17
New cards

What should be monitored when Aprepitant is given IV?

Cardiac monitoring, especially if the patient is at risk for arrhythmia.

18
New cards

What drug interaction requires dosage adjustment with Aprepitant?

Dexamethasone dose must be reduced by 50% (oral) or 25% (IV) if given together.

19
New cards

What is a significant finding from Navari et al. (2021) regarding Akynzeo?

Akynzeo was found to be more effective than aprepitant regimens for delayed N/V.

20
New cards

What did the study about Akynzeo find regarding medication needs?

It reduced the need for rescue meds.

21
New cards

What lifestyle modification should be made regarding grapefruit juice when taking Aprepitant?

Avoid grapefruit juice due to its interaction with CYP3A4 drugs.

22
New cards

What are the common side effects of Aprepitant?

Fatigue, headache, dizziness, and hiccups.

23
New cards

What is the significance of the BLACK BOX warning for Fosaprepitant?

Risk of abnormal heart rhythm.

24
New cards

What clinical considerations are important when administering Aprepitant?

Monitor for drug interactions and QT prolongation.

25
New cards

What combination is essential with Aprepitant to improve treatment efficacy?

Combination with 5-HT3 antagonists and corticosteroids.

26
New cards

When should the backup method for birth control be used when taking Aprepitant?

For up to 28 days after the last dose.

27
New cards

What is the primary target of Aprepitant in chemotherapy-induced conditions?

Delayed nausea and vomiting.

28
New cards

What should be done if a patient experiences side effects while on Aprepitant?

Assess and monitor the patient for side effects post-chemo.

29
New cards

What types of patients should be particularly monitored when receiving Aprepitant?

Patients at risk for arrhythmias.

30
New cards

How does Aprepitant affect the nausea signal in the body?

It interrupts the signal by blocking NK1 receptors.

31
New cards

What should be done if nausea/vomiting is not controlled after chemotherapy?

Assess the effectiveness of the antiemetic regimen.

32
New cards

What is the potential impact of using other medications with Aprepitant?

Increased risk of QT prolongation and drug interactions.

33
New cards

What is the preferred route of administration for Fosaprepitant?

IV administration is discouraged due to associated risks.

34
New cards

What can patients do to avoid drug interaction issues while on Aprepitant?

Consult healthcare providers before taking additional medications.